Literature DB >> 28596202

Persistent lesion hyperintensity on brain diffusion-weighted MRI is an early sign of intravascular lymphoma.

Takashi Kageyama1,2, Haruo Yamanaka1, Fumihiko Nakamura3, Toshihiko Suenaga1.   

Abstract

A 63-year-old man presented with right-sided hemianopia and unsteady gait. Brain MRI revealed multiple hyperintense infarct-like lesions on diffusion-weighted images (DWI). Hyperintensity persisted in some of these lesions even after 6 weeks, although his symptoms were ameliorated then. The patient developed episodic dizziness and a transient event of apraxia at 18 weeks after the first episode. Brain MRI revealed additional hyperintense lesions on DWI, which persisted even after 7 weeks. Eventually, the patient manifested cauda equina syndrome 39 weeks after the first episode. Brain MRI showed the presence of new lesions in addition to the persistent hyperintense lesions on DWI over 21 weeks in the right frontal lobe. Based on laboratory findings and the pathological assessment of bone marrow and random skin biopsies, the patient was diagnosed with intravascular lymphoma (IVL). Persistent hyperintense lesions on DWI of brain MRI may precede the clinical exacerbation of IVL. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  haematology (incl blood transfusion); neuroimaging; neurology; neurooncology

Mesh:

Year:  2017        PMID: 28596202      PMCID: PMC5534976          DOI: 10.1136/bcr-2017-220099

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  8 in total

1.  Characteristics of intravascular large B-cell lymphoma on cerebral MR imaging.

Authors:  A Yamamoto; Y Kikuchi; K Homma; T O'uchi; S Furui
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-15       Impact factor: 3.825

2.  Intravascular lymphoma: magnetic resonance imaging correlates of disease dynamics within the central nervous system.

Authors:  J M Baehring; C Henchcliffe; C J Ledezma; R Fulbright; F H Hochberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-04       Impact factor: 10.154

3.  An autopsy case of intravascular large B-cell lymphoma with subcortical U-fiber sparing and unique lymphocyte markers.

Authors:  Kota Sato; Emi Motokura; Kentaro Deguchi; Mami Takemoto; Nozomi Hishikawa; Yasuyuki Ohta; Toru Yamashita; Junya Itakura; Koji Abe
Journal:  J Neurol Sci       Date:  2016-08-26       Impact factor: 3.181

4.  Clinical significance of detection of multiple acute brain infarcts on diffusion weighted magnetic resonance imaging.

Authors:  V Caso; K Budak; D Georgiadis; B Schuknecht; R W Baumgartner
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-04       Impact factor: 10.154

5.  Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin's lymphoma: comparison with serum soluble interleukin-2 receptor values.

Authors:  Mitsuaki Tatsumi; Hiroyuki Sugahara; Ichiro Higuchi; Hiroki Fukunaga; Hironobu Nakamura; Yuzuru Kanakura; Jun Hatazawa
Journal:  Int J Clin Oncol       Date:  2009-04-24       Impact factor: 3.402

6.  A clinicopathological study of 13 cases of intravascular lymphoma: experience in a single institution over a 9-yr period.

Authors:  Kosei Matsue; Noboru Asada; Masami Takeuchi; Masayuki Yamakura; Shun-ichi Kimura; Jun Odawara; Takatoshi Aoki
Journal:  Eur J Haematol       Date:  2007-12-07       Impact factor: 2.997

7.  Intravascular lymphomatosis mimicking primary central nervous system lymphoma: a case report and literature review.

Authors:  Masahiro Oomura; Noriyuki Sakakibara; Shugo Suzuki; Atsushi Wakita; Yuji Mori; Kaoru Kamimoto
Journal:  Case Rep Neurol       Date:  2014-03-29

8.  Long-term complete remission in a patient with intravascular large B-cell lymphoma with central nervous system involvement.

Authors:  Takeshi Sawada; Yasushi Omuro; Takeshi Kobayashi; Tunekazu Hishima; Fumiaki Koizumi; Yusuke Kanemasa; Tatsu Shimoyama; Eisaku Sasaki; Yoshiharu Maeda
Journal:  Onco Targets Ther       Date:  2014-11-18       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.